EGFR M766Q

CI-VAR-00002609Explore in graph →CIViC 2745

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma3
EGFR M766Q	Neratinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID7389 L858R and L858R/M766Q mutations were retrovirally introduced into Ba/F3 and NIH/3T3 cells and evaluated for sensitivity to various EGFR inhibitors. Modeling suggested that EGFR M766Q could disrupt osi… (full text at CIViC) PMID 31254668 · Castellano et al., 2019 · Open in CIViC	civic
EGFR M766Q	Osimertinib	Predictive	C	Supports Resistance	3	submitted	EID7388 A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer. Sequencing of circulating cell-free DNA showed EGFR L858R, an acqui… (full text at CIViC) PMID 31254668 · Castellano et al., 2019 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.